TherVacB is an EU-funded project with a duration of seven years from January 2020 to December 2026. The clinical trial evaluating the TherVacB vaccine is designed as a randomized, open-label, multicenter Phase 1/2 study to assess safety and tolerability and to collect initial efficacy data of the therapeutic hepatitis B vaccine candidate in patients with chronic hepatitis B.